Clinical Trial Update: Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating intra-lymphatic STI-3031 delivered with the Sofusa DoseConnect device for in-transit melanoma (clinical stage III cutaneous melanoma)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• STI-3031

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma | Phase 1 | Status: TERMINATED